Author
Listed:
- Aidan M. Tousley
(Stanford University School of Medicine)
- Maria Caterina Rotiroti
(Stanford University School of Medicine)
- Louai Labanieh
(Stanford University
Parker Institute for Cancer Immunotherapy)
- Lea Wenting Rysavy
(Stanford University School of Medicine)
- Won-Ju Kim
(Stanford University School of Medicine)
- Caleb Lareau
(Parker Institute for Cancer Immunotherapy
Stanford University School of Medicine
Stanford University School of Medicine)
- Elena Sotillo
(Stanford University School of Medicine)
- Evan W. Weber
(Parker Institute for Cancer Immunotherapy
University of Pennsylvania)
- Skyler P. Rietberg
(Stanford University School of Medicine)
- Guillermo Nicolas Dalton
(Stanford University School of Medicine)
- Yajie Yin
(Parker Institute for Cancer Immunotherapy
Stanford University School of Medicine
Stanford University School of Medicine)
- Dorota Klysz
(Stanford University School of Medicine)
- Peng Xu
(Stanford University School of Medicine)
- Eva L. Serna
(Stanford University)
- Alexander R. Dunn
(Stanford University
Stanford University School of Medicine
Stanford University)
- Ansuman T. Satpathy
(Parker Institute for Cancer Immunotherapy
Stanford University School of Medicine
Stanford University School of Medicine)
- Crystal L. Mackall
(Stanford University School of Medicine
Parker Institute for Cancer Immunotherapy
Stanford University School of Medicine
Stanford University School of Medicine)
- Robbie G. Majzner
(Stanford University School of Medicine
Parker Institute for Cancer Immunotherapy
Stanford University School of Medicine)
Abstract
Although chimeric antigen receptor (CAR) T cells have altered the treatment landscape for B cell malignancies, the risk of on-target, off-tumour toxicity has hampered their development for solid tumours because most target antigens are shared with normal cells1,2. Researchers have attempted to apply Boolean-logic gating to CAR T cells to prevent toxicity3–5; however, a truly safe and effective logic-gated CAR has remained elusive6. Here we describe an approach to CAR engineering in which we replace traditional CD3ζ domains with intracellular proximal T cell signalling molecules. We show that certain proximal signalling CARs, such as a ZAP-70 CAR, can activate T cells and eradicate tumours in vivo while bypassing upstream signalling proteins, including CD3ζ. The primary role of ZAP-70 is to phosphorylate LAT and SLP-76, which form a scaffold for signal propagation. We exploited the cooperative role of LAT and SLP-76 to engineer logic-gated intracellular network (LINK) CAR, a rapid and reversible Boolean-logic AND-gated CAR T cell platform that outperforms other systems in both efficacy and prevention of on-target, off-tumour toxicity. LINK CAR will expand the range of molecules that can be targeted with CAR T cells, and will enable these powerful therapeutic agents to be used for solid tumours and diverse diseases such as autoimmunity7 and fibrosis8. In addition, this work shows that the internal signalling machinery of cells can be repurposed into surface receptors, which could open new avenues for cellular engineering.
Suggested Citation
Aidan M. Tousley & Maria Caterina Rotiroti & Louai Labanieh & Lea Wenting Rysavy & Won-Ju Kim & Caleb Lareau & Elena Sotillo & Evan W. Weber & Skyler P. Rietberg & Guillermo Nicolas Dalton & Yajie Yin, 2023.
"Co-opting signalling molecules enables logic-gated control of CAR T cells,"
Nature, Nature, vol. 615(7952), pages 507-516, March.
Handle:
RePEc:nat:nature:v:615:y:2023:i:7952:d:10.1038_s41586-023-05778-2
DOI: 10.1038/s41586-023-05778-2
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Pei Liu & Josquin Foiret & Yinglin Situ & Nisi Zhang & Aris J. Kare & Bo Wu & Marina N. Raie & Katherine W. Ferrara & Lei S. Qi, 2023.
"Sonogenetic control of multiplexed genome regulation and base editing,"
Nature Communications, Nature, vol. 14(1), pages 1-11, December.
- Shiyu Zuo & Chuo Li & Xiaolei Sun & Biping Deng & Yibing Zhang & Yajing Han & Zhuojun Ling & Jinlong Xu & Jiajia Duan & Zelin Wang & Xinjian Yu & Qinlong Zheng & Xiuwen Xu & Jiao Zong & Zhenglong Tian, 2024.
"C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial,"
Nature Communications, Nature, vol. 15(1), pages 1-20, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:615:y:2023:i:7952:d:10.1038_s41586-023-05778-2. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.